ISSUE 09

In this issue:

  Micrima to develop new imaging technology for breast cancer screening
  ProVision Communications wins funding for a wireless future
  CMS SupaTrak set for growth following investment
  Atlas Genetics secures £2m to develop sub-30 minute test
 
 

Micrima to develop new imaging technology for breast cancer screening

YFM Group and Swarraton Partners have co-led a £2 million investment in Micrima, a Bristol University spin-out.

Micrima is developing radio wave technology to improve detection of breast cancer. The imaging system captures high-resolution, 3D images through the use of radio waves and has the potential to offer several advantages over existing primary screening technology.

The initial investment will fund technical development and further clinical trials at Frenchay Hospital’s Breast Clinic in Bristol. Clinical work will then be extended to include women from other centres around the UK.

Read more »
 
 

ProVision Communications wins funding
for a wireless future

ProVision Communications has secured £300,000 of venture capital from the South West Ventures Fund as part of a £750,000 funding round.

The firm develops wireless video solutions ranging from in-home media gateways to wireless video systems for sports and other spectator events.

The technology was used to enable real-time multicast video streaming over WiFi at the 2007 World Rally Championship (WRC) Wales Rally GB, where spectators were able to select video channels showing different parts of the rally course.

ProVision

Read more »
 
 

CMS SupaTrak set for growth following investment

CMS SupaTrak has obtained £300,000 in second round funding from the South West Ventures Fund.

The Swindon-based company provides vehicle/asset tracking and mobile workforce solutions to commercial fleet companies, couriers and local government. Customers include Royal Mail, Network Rail and Hampshire County Council.

The company is chaired by the former UK Vodafone Corporate Managing Director, Graham Ward.

Read more »

 
 

Atlas Genetics secures £2 million to develop
sub-30 minute test

South West Ventures Fund has led a £2.1m further funding round in Bath University spin-out Atlas Genetics, which is developing point-of-care diagnostic technology.

The Velox™ system delivers the benefits of molecular testing together with laboratory quality results, all within 30 minutes.

The funding will allow Atlas Genetics to conduct a clinical evaluation for point-of-care detection of Group B Streptococcus in pregnant women, an infection which can lead to sepsis and meningitis in neo-natal children.

atlas

Read more»

For further information please contact the YFM Group team in Bristol: Peter Davies, Julian Dennard, Nick Simmonds, or Alison Briggs.

If you are having trouble viewing this email click here
 
 

Disclaimer

The South West Ventures Fund is managed by YFM Venture Finance Limited, part of the YFM Group. The fund management subsidiaries of YFM Group, YFM Venture Finance Limited and YFM Private Equity are authorised and regulated by the Financial Services Authority.

Whilst YFM Venture Finance has taken all reasonable steps to ensure that the information contained within these pages is accurate and up-to-date, no liability can be accepted for any error or omissions appearing in this site.

If you are in any doubt as to the validity of information made available within these pages, or if you wish to rely on this information, then it may be in your best interests to seek verification by contacting us.

  
 

If you wish to unsubscribe, please send an email to joanne.cole@yfmgroup.co.uk with the subject heading 'Unsubscribe Me'